Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cimdelirsen extension in acromegaly
NCT03967249Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Jul 2019
- Primary completion
- Mar 2022
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 6
01
Overview
A Phase 2 trial of cimdelirsen in acromegaly, sponsored by Ionis Pharmaceuticals. Started Jul 2019; status: completed.
02
Drugs
cimdelirsen
03
Conditions
acromegaly
Beyond the preview
Go deeper on NCT03967249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03967249.